Clinical Trial: STRO-002-GM2

Trial Status: Open
Disease Type: Gynecologic
Trial ID STRO-002-GM2
Sponsor ID Sutro Biopharma

A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor alpha Antibody Drug Conjugate (ADC), in Combination with Bevacizumab in Patients with Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers).

1 Location

Locations

Fairfax Office

Learn More About This Trial

Other Relevant Trials
Trial ID 21457
Sponsor ID Artistry-7

(ALKS 4230-007/GOG-3063) A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7)

Principal Investigator
Robert L. Marsh, MD
5 Locations
Trial ID 21369
Sponsor ID PICCOLO

PICCOLO: A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression

Principal Investigator
Robert L. Marsh, MD
3 Locations